Palavras-chave
Biomarcadores moleculares
Prognóstico
Como Citar
Copyright © | Todos os direitos reservados.
A revista detém os direitos autorais exclusivos de publicação deste artigo nos termos da lei 9610/98.
Reprodução parcial
É livre o uso de partes do texto, figuras e questionário do artigo, sendo obrigatória a citação dos autores e revista.
Reprodução total
É expressamente proibida, devendo ser autorizada pela revista.
Resumo
Objetivo: Realizar a identificação dos biomarcadores moleculares com maior capacidade preditiva para auxiliar no diagnóstico, na definição prognóstica e na avaliação da resposta às terapias individualizadas em indivíduos com linfoma não Hodgkin (LNH). Métodos: Trata-se de uma revisão de literatura, realizada por meio de busca nas bases científicas Pubmed, Scielo e Biblioteca Virtual de Saúde. Foram selecionados 24 estudos publicados, priorizando ensaios clínicos, estudos prospectivos, retrospectivos e multicêntricos, que abordaram biomarcadores moleculares associados aos desfechos clínicos em pacientes com LNH. Resultados: Os estudos analisados destacaram que biomarcadores como TP53, MYC, BCL2, KMT2D, CREBBP, SOCS1, além da análise do DNA tumoral circulante (ctDNA), são fundamentais para estratificação prognóstica e definição de estratégias terapêuticas em LNH. Além disso, a identificação de clusters moleculares (MCD, BN2, EZB, ST2 e N1) e a classificação pela célula de origem (COO) possibilitam uma predição mais precisa dos desfechos clínicos, especialmente em terapias como CAR-T e anticorpos biespecíficos. Considerações finais: Os biomarcadores moleculares otimizam o diagnóstico e o manejo terapêutico dos LNH, porém a heterogeneidade metodológica limita a generalização dos resultados.
Referências
ALCOCEBA MA, et al. Liquid biopsy for molecular characterization of diffuse large B‐cell lymphoma and early assessment of minimal residual disease. British Journal of Haematology, 2024; 205(1): 109-121.
ALCOCEBA MA, et al. Molecular characterization of diffuse large‐B cell lymphoma by liquid biopsy at diagnosis and during follow‐up. Hematological Oncology, 2023; 41: s/p.
ALMEIDA AB, et al. Acompanhamento do seguimento terapêutico de pacientes: jornada do paciente com linfoma não hodgkin no Brasil. Hematology, Transfusion and Cell Therapy, 2021; 43: S62.
BATLEVI CL, et al. Correlative biomarkers for CART19 response in patients with relapsed or refractory diffuse large B-cell lymphoma. Blood, 2022; 140(Supl. 1): 9228-9230.
COOPER AB, et al. CD5 gene signature identifies diffuse large B-cell lymphomas sensitive to Brutonʼs tyrosine kinase inhibition. Journal of Clinical Oncology, 2024; 42(4): 467-480.
DUBOIS SD, et al. Next-generation sequencing in diffuse large B-cell lymphoma highlights molecular divergence and therapeutic opportunities: a LYSA study. Clinical Cancer Research, 2016; 22(12): 2919-2928.
HILL BT, et al. Impact of molecular features of diffuse large B-cell lymphoma on treatment outcomes with anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. Blood, 2021; 138: 165.
IRAOLA-TRUCHUELO JT, et al. Resistance mechanisms impacting bispecific antibody (BsAbs) and chimeric antigen receptor (CAR) T-cell therapy outcomes in large B cell lymphoma (LBCL) patients. Blood, 2023; 142(Supl. 1): 1635.
KENDALL EK, et al. Integrative DNA methylation and gene expression analysis reveals candidate biomarkers associated with dichotomized response to chemoimmunotherapy in diffuse large B-cell lymphoma. Blood, 2020; 136: 22.
KURTZ DM, et al. Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma. Journal of Clinical Oncology, 2018; 36(28): 2845-2853.
KURTZ DM, et al. Development of a dynamic model for personalized risk assessment in large B-cell lymphoma. Blood, 2017; 130(1): s/p.
LINO LA, et al. Uso dos biomarcadores na detecção precoce de câncer: uma revisão de literatura. Research, Society and Development, 2024; 13(8): e4013846517.
LIU WD, et al. Harnessing ctDNA to predict therapeutic success in DLBCL: insights from a multicenter prospective study. Blood, 2024; 144(Supl. 1): 4347.
MARQUES AP, et al. Taxa de sobrevida em pacientes pediátricos com linfoma não-Hodgkin e fatores prognósticos: revisão da literatura. Brazilian Journal of Health Review, 2021; 4(5): 22543-22556.
MOIA RD, et al. Molecular clustering on ctDNA may improve prognostic stratification of DLBCL patients. Blood, 2022; 140(Supl. 1): 9226-9227.
OLSON NE, et al. Exploration of tumor biopsy gene signatures to understand the role of the tumor microenvironment in outcomes to lisocabtagene maraleucel. Molecular Cancer Therapeutics, 2023; 22(3): 406-418.
OMIZZOLO HR, et al. Rosai-Dorfman como diagnóstico diferencial de linfadenomegalia cervical: relato de caso. Brazilian Journal of Health Review, 2021; 4(6): 29350-29353.
PEREZ LP, et al. Diffuse large B cell lymphoma genetic classification by targeted sequencing and associations with immunochemotherapy-treated patients' clinical outcome. Blood, 2020; 136: 24-25.
QUIVORON CV, et al. High incidence of TP53 and epigenetic modifying oncogenes mutations in a large cohort of patients enrolled in phase 1 clinical trials for relapsed or refractory diffuse large B-cell lymphoma. Blood, 2020; 136: 10-11.
RODRÍGUEZ MR, et al. An integrated prognostic model for diffuse large B‐cell lymphoma treated with immunochemotherapy. EJHaem, 2022; 3(3): 722-733.
SAUZA-ROLDAN JV, et al. Linfoma primario en intestino delgado: reporte de dos casos y revisión de literatura. Caribe, 2022; 6: s/p.
SONG JY, et al. New genomic model integrating clinical factors and gene mutations to predict overall survival in patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood, 2018; 132: 346.
SWORDER BJ, et al. Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas. Cancer Cell, 2023; 41(1): 210-225.e5.
TABARI ES, et al. Molecular characteristics and disease burden metrics determined by next-generation sequencing on circulating tumor DNA correlate with progression free survival in previously untreated diffuse large B-cell lymphoma. Blood, 2019; 134: 490.
THAKKAR DE, et al. Molecular and clinical determinants of CAR-T therapy response in DLBCL. Blood, 2024; 144(Supl. 1): 3409.
TZANKOV AL, et al. Multiparameter analysis of homogeneously R-CHOP-treated diffuse large B-cell lymphomas identifies CD5 and FOXP1 as relevant prognostic biomarkers: report of the prospective SAKK 38/07 study. Journal of Hematology & Oncology, 2015; 8: 1-11.
VALLANIA FR, et al. Identification of predictive biomarkers for response of R/R DLBCL patients treated with loncastuximab tesirine using low pass whole-genome sequencing (WGS). Blood, 2022; 140(Supl. 1): 3551-3552.
ZHOU LN, et al. Establish[ment of a dynamic ctDNA monitoring system to predict the prognosis of CAR-T cell therapy in R/R B-NHL patients. Blood, 2023; 142: 2278.